Serologicals

and Millipore

Creating a global leader in life science tools

In order to take advantage of the safe harbor provisions of the private securities litigation reform act of

1995, you should understand that we will be making forward-looking statements in this conference.

These statements involve a number of risks and uncertainties, including those which are set forth in

our annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and our other SEC

filings. We assume no obligation to update any forward-looking statement based on new information,

future events or any other reason.  A reconciliation of non-GAAP to GAAP results is available on the

company’s website.

This material is not a substitute for the proxy statement Serologicals

will file with the Securities and

Exchange Commission.  Investors are urged to read the proxy statement when it becomes available,

because it will contain important information.  The proxy statement and other documents which will be

filed

by

Serologicals

with

the

Securities

and

Exchange

Commission

will

be

available

on

the

SEC’s

website, www.sec.gov.  Serologicals

and certain of its directors, executive officers and certain other

members of its management may be deemed to be soliciting proxies

from Serologicals

shareholders

in

connection

with

the

proposed

transaction.

Investors

may

obtain

a

detailed

list

of

names,

affiliations and interests of Serologicals

participants in the solicitation of proxies of Serologicals

shareholders by reading the proxy statement when it becomes available.

Forward-looking Statements / Reg. G-Proxy

Creating a global leader in life science tools

Who is Millipore?

Combined company: what it means

Next steps

Millipore: critical to life science researchers and

bioprocess engineers

Strong brand worldwide

Stands for quality,

performance, dependability,

support

Brand execution: 1,100

scientists and specialists in

field

Critical to biotherapeutic

production

Important to research and

analysis

We’re organized into two customer-focused

divisions

Millipore

•

Analytical

•

Clinical

•

Research

•

Biotech

•

Pharmaceutical

•

Niche Beverage

Bioscience

Bioprocess

Millipore Bioscience: thousands of products to

improve productivity in the bioscience lab

Millipore Bioprocess: products and services to

improve productivity in bioprocessing

People are our competitive advantage: example -

field scientists and applications specialists

Close relationships with all biotech/pharma

Involved from pre-clinical through full scale

manufacturing

Involved from the bench idea to the blockbuster

A key competitive advantage: our worldwide

infrastructure

Three major manufacturing centers of excellence

31 offices/subsidiaries

Direct sales on ground everywhere

Major initiative in emerging markets of China and India

New strategy launched in June 2005

Accelerate growth  -

double value

Accelerate innovation -

inside & outside

Acquired NovAseptic AB, Microsafe BV

Agreement to acquire Newport Biosystems

Millipore strategic goals

Strengthen leadership position with biopharmaceutical

customers

Become a strategic supplier in bioscience research

markets

Lead industry in product quality and manufacturing

effectiveness

Become a magnet for talent

Double the value of the company by 2009

Creating a global leader in life science tools

Who is Millipore?

Combined company: what it means

Next steps

You have a great track record of success!

Customer satisfaction

Financial results

High growth market

segments

Rapid innovation

Talented people

Successful acquisitions

New Product Launches

Revenue Per New Product

2003

2004

2005

$5,797

$6,600

$8,500

2005

1,700

Source: Serologicals

2004

2003

1,215

930

Serologicals: strong track record of innovation

Leader in cell culture

supplements

Highly productive

R&D organization

Strong brand and

customer relationships

Innovative, broad

Bioscience portfolio

Global direct sales force

#1 in downstream

bioprocessing, lab water, and

life science filtration

Complementary strengths of each company

Bioscience

40%

Bioprocess

60%

Organizationally -

a perfect fit

Research

-Upstate

-Chemicon

60%

Celliance

40%

Millipore

Serologicals

-Bioscience

-Research

42%

-Bioprocess

-Celliance

58%

2006 Revenues

*

Combined

Company

*Forecasted Pro Forma revenue

For Serologicals -

a wider global reach

Same markets, same type of customers

Combined sales organization a powerhouse

For Millipore -

a broader product portfolio

Same markets, same types

of customers

Model for rapid product

development

2X NA sales coverage in

Bioscience

Innovative scientists &

engineers

2005 Organic Revenue Growth Rate

0%

2%

4%

6%

8%

10%

12%

14%

16%

18%

Serologicals

Millipore

Qiagen

Invitrogen

Affymetrix

Sigma-Aldrich

Fisher

16%

10%

9%

6%

6%

5%

5%

Source: Company Filing and Wall Street research

Combining two dynamic and growing

companies will create a powerful new force

Sigma-Aldrich

Serologicals

2005 Life Science Revenue

0

5,000

Serologicals

+ Millipore

Millipore

Qiagen

Invitrogen

Affymetrix

Fisher

1,266

1,198

991

398

368

275

Source: UBS

1,667

4,141

500

1,000

1,500

4,000

Third largest life science consumables company

Strengthening our position in bioprocessing

Process

development

and scale-up

Upstream

processing

Downstream

purification and

filtration

Ongoing

compliance

monitoring

and testing

Filtration and chromatography

Disposable Solutions

Process Monitoring Tools

Cell Culture

Supplements

Serologicals

Millipore

Millipore Bioprocess Today

Millipore +

Serologicals

Chromatography

& Filtration

62%

Components & Systems

16%

Process

Monitoring Tools

20%

Systems and

Components

13%

Process Monitoring Tools

16%

Chromatography

& Filtration

49%

Cell Culture Supplements

14%

Services

3%

Services

2%

2005 Revenues

Together we bring a more complete bioprocessing

solution to biotech and pharma

Antibody

Technology

Protein

Research

Multiplex

Technologies

Stem

Cells

9%

15%

15%

15-20%

Drug

Discovery

14%

Estimated market CAGR 2006-2011

Source:  LEK Consulting

In bioscience we address a broader array of

attractive market segments

9%

Nuclear

Function

Advanced

Life Science

Tools

Laboratory Water Systems

Laboratory Filtration and Sample Prep

Millipore

Bioscience Today

Millipore

+ Serologicals

Lab Filtration and

Sample Prep

47%

Service

10%

Lab Water

43%

Service

8%

Lab Water

31%

Antibodies

11%

Drug Discovery

6%

Cell Biology

9%

Lab Filtration and

Sample Prep

35%

2005 Revenues

Together we make a big leap in our presence in

the research lab

% of life science sales force by geography

Serologicals

Millipore

Asia

14%

South

America

7%

Japan

11%

North

America

19%

Europe

49%

North

America

64%

Europe

30%

Asia

2%

Japan

2%

South

America

2%

Our sales forces are a great fit as well

Millipore

and Serologicals: $1.4 billion revenue,

Life Science company

Better able to compete

Accelerated pace of growth

and innovation

Broad array of productivity

tools for research and drug

discovery

Broad array of productivity

tools upstream/downstream

of bioreactor

Strong global reach

Creating a global leader in life science tools

Who is Millipore?

Combined company: what it means

Next steps

Anticipated Close

Integration plans

Steering Committee

April 25

Announcement

~ June 30

Program Management Office

Integration Teams

INTEGRATION PLANNING

INTEGRATION